<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **HODG-12**              | The panel consensus supported the following changes to the second-line therapy options for those with suspected relapsed CHL:  
• Initial stage IA-IIA (no prior RT with failure in initial sites)  
  o Second-line therapy modified for patients who received abbreviated chemotherapy (3–4 cycles) without RT:  
    ▪ Option removed: RT alone in highly selected cases.  
    ▪ Option modified: *Second-line systemic therapy followed by HDT/ASCR ± ISRT*  
  o Second-line therapy modified for patients who received full-course chemotherapy: Second-line systemic therapy ±RT or *followed by HDT/ASCR ± ISRT*  
• All others  
  o Second-line therapy modified: Second-line systemic therapy *followed by HDT/ASCR ± ISRT* | YES | NO | ABSTAIN | ABSENT |
|                           |                           | 17              | 0   | 4        | 9      |